The global market for coagulation factors is experiencing significant growth, driven by the increasing prevalence of bleeding disorders, including hemophilia A and B, as well as von Willebrand disease. This surge is accompanied by a rising adoption of both recombinant and plasma-derived therapies. Breakthroughs in long-acting treatments and gene-based therapies are revolutionizing patient care,...